For those who want to understand the landscape of potential COVID-19 experimental “vaccine” mandates in the United States, this article recently published in the Journal of the American Medical Association is a must read. Once the COVID-19 experimental “vaccine” transitions from Emergency Use Authorization status to Full Biologics License approval, the door is open for mandated COVID-19 inoculation in a variety of settings, include places of employment, educational settings, some states, and even as a condition of receiving services. The article says nothing of then scientifically proven safe and effective alternative treatments such as Hydroxychloroquine or Ivermectin.
Published by markskidmore
Mark Skidmore is Professor of Economics at Michigan State University where he holds the Morris Chair in State and Local Government Finance and Policy. His research focuses on topics in public finance, regional economics, and the economics of natural disasters. Mark created the Lighthouse Economics website and blog to share economic research and information relevant for navigating tumultuous times. View more posts